Skip to content

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

ALX148 Blocks CD47 and Enhances Innate and Adaptive Antitumor Immunity with a Favorable Safety Profile

Post navigation

Previous: A Phase 1 Study of ALX148: CD47 Blockade in Combination with Anti-Cancer Antibodies to Bridge Innate and Adaptive Immune Responses for Advanced Malignancy

Next: Discovery of Monoclonal Antibodies Targeting Myeloid Checkpoint SIRPα to Enhance Anti-Tumor Immunity

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn